List of Fleqsuvy drug patents

Fleqsuvy is owned by Azurity.

Fleqsuvy contains Baclofen.

Fleqsuvy has a total of 2 drug patents out of which 0 drug patents have expired.

Fleqsuvy was authorised for market use on 04 February, 2022.

Fleqsuvy is available in suspension;oral dosage forms.

Fleqsuvy can be used as indicated for the treatment of spasticity resulting from multiple sclerosis.

The generics of Fleqsuvy are possible to be released after 29 September, 2037.

Can you believe FLEQSUVY received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446246 AZURITY Suspensions and diluents for metronidazole and baclofen
Sep, 2037

(14 years from now)

US11324696 AZURITY Suspensions and diluents for metronidazole and baclofen
Sep, 2037

(14 years from now)

Do you want to check out FLEQSUVY patents from before 2022?

Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 04 February, 2022

Treatment: Indicated for the treatment of spasticity resulting from multiple sclerosis

Dosage: SUSPENSION;ORAL

How can I launch a generic of FLEQSUVY before it's patent expiration?
More Information on Dosage

FLEQSUVY family patents

11

United States

1

China

1

Canada

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in